ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming SVB Leerink 11th Annual Global Healthcare Conference

Rhea-AI Summary

ImmunoGen, Inc. (NASDAQ: IMGN) announced participation in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 10:00 AM ET. Chief Financial Officer Susan Altschuller and Chief Medical Officer Anna Berkenblit will represent the company. The presentation will be available via webcast in the Investors and Media section of the company's website, with a replay provided post-event.

ImmunoGen focuses on developing advanced antibody-drug conjugates to enhance cancer treatment.

Positive

• Participation in a significant healthcare conference may enhance visibility and attract investor interest.
• Webcast availability could improve shareholder engagement and transparency.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming virtual SVB Leerink 11th Annual Global Healthcare Conference. The presentation is scheduled for February 18, 2022 at 10:00am ET.

A webcast of the presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220204005016/en/

INVESTOR RELATIONS AND MEDIA CONTACTS

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

FAQ

When will ImmunoGen participate in the SVB Leerink Annual Global Healthcare Conference?

ImmunoGen will participate in the SVB Leerink Annual Global Healthcare Conference on February 18, 2022, at 10:00 AM ET.

Who from ImmunoGen will participate in the upcoming conference?

CFO Susan Altschuller and CMO Anna Berkenblit will represent ImmunoGen at the conference.

How can I access the webcast of ImmunoGen's conference presentation?

The webcast can be accessed through the 'Investors and Media' section of ImmunoGen's website.

What is ImmunoGen's focus in cancer treatment?

ImmunoGen is developing next-generation antibody-drug conjugates to improve cancer patient outcomes.